Juan J. Diaz Mochon

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA.

MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.

Erasmus MC operates as an academic hospital. It is affiliated with the Erasmus University of Rotterdam, and home to its faculty of medicine. It has special units such as Neurosurgery, Cardiograph surgery, Neonatal and pediatric surgery and intensive care, Pediatric oncology and Level I trauma center. The company was founded in 2002 and is headquartered in Rotterdam, Netherlands.

Cytox Ltd. develops products and services for neurodegenerative disorders. It develops cellular and genetic assays for Alzheimer’s disease diagnosis. The firm offers biomarker services to pharmaceutical companies conducting clinical trials with drugs for the treatment of AD and mild cognitive impairment; and drug-screening services. The company was founded by Zsuzsanna Nagy, Margaret Esiri, Roy Bicknell and James S. Chadwick in 2004 and is headquartered in Oxford, the United Kingdom.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

DxS Ltd. is a personalized medicine company which engages in the development and manufacture of companion diagnostic products. Its products make use of molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. It offers its products, technology, and services to the healthcare industry to enable the delivery of safe and effective medicines. The company was founded by David Whitcombe in 2001 is headquartered in Manchester, the United Kingdom.

Biofortuna Ltd. provides molecular diagnostic solutions. Its products include SSPGo and ReadyPlex. The firm offers design and development, freeze-drying, manufacturing and dispensing and kitting services. The firm offers its technology on a custom service basis to clients from the clinical, veterinary, food, and research sectors. The company was founded by Mike Bunce, Ben Passey and David Charvill in 2008 and is headquartered in Wirral, the United Kingdom.

ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands.

Catapult Ultimate Holdings Ltd (Catapult Ultimate Holdings) is an independent venture capital firm founded in 1999. The firm is headquartered in Leicester, United Kingdom.

Novigenix SA develops molecular diagnostics for cancer. The firm specializes in new generation liquid biopsy tests for early detection of cancer and precision medicine. The company was founded by Sahar Hosseinian in 2014 and is headquartered in Epalinges, Switzerland.

Saving Patients' Lives Medical BV develops and manufactures nano-sized iron oxide particles for effective diagnostics of cancer metastasis. The company was founded by Ari Aminetzah and Patrik Zamecnik in 2015 and is headquartered in Nijmegen, the Netherlands.

ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom.

Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022.

OxDX Ltd. builds instant pathogen test detection using resolution microscopy and machine learning. The company is based in Headington, UK. The British company was founded by Alex Batchelor, Nicolas Shiaelis, and Nicole Robb. Alex Batchelor has been the CEO since incorporation.